European Society of Gene and Cell Therapy
European Society of Gene & Cell Therapy (ESGCT) formerly European Society of Gene Therapy (ESGT) is a legally registered professional body which emerged from a small working group in 1992 that focused on human gene therapy.
The objectives of the ESGT include the following:
- promote basic and clinical research in gene therapy;
- facilitate education (and the exchange of information and technologies) related to gene transfer and therapy;
- serve as a professional adviser to the gene therapy community and various regulatory bodies in Europe.
The official journal of the ESGT is The Journal of Gene Medicine.
Collaborations[edit]
The ESGT works with other entities in the scientific communities in the event that an adverse effect to a specific gene therapy is discovered. Investigations the ESGT has been involved with include the adverse effects discovered during the French X-SCID gene therapy trial. The ESGT hosted a forum of 500 researchers from various facilities around the world, including representatives from the Stanford University and the Sloan Kettering Cancer Research Center.
External links[edit]
- Official Site
- Researchers from Israel, Southern California to Present Stem Cell Symposium
- Researchers team up to tackle cystic fibrosis
 | This genetics article is a stub. You can help Wikipedia by expanding it. |